Phase I trial of LYC-30937 for the treatment of inflammatory bowel disease
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2016
At a glance
- Drugs LYC 30937 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Lycera
- 18 Mar 2016 Status changed from recruiting to completed, according to a Lycera media release.
- 30 Apr 2015 Status changed from planning to recruiting according to a Lycera Corporation media release.
- 11 Mar 2015 New trial record